Menu
Back to User profile » Dr Karen MacDonald
Papers published by Dr Karen MacDonald:
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
Van Aken E, Favreau M, Ramboer E, Denhaerynck K, MacDonald K, Abraham I, Brié H
Clinical Ophthalmology 2020, 14:4173-4185
Published Date: 2 December 2020
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
Leys AM, Ramboer E, Favreau M, Denhaerynck K, MacDonald K, Abraham I, Brié H
Clinical Ophthalmology 2020, 14:1473-1481
Published Date: 2 June 2020
Detectability and acceptability of continuous pulse signals for the MemoPatch® device, an electronic skin patch intended to deliver tactile medication reminder signals
Abraham I, De Geest J, De Geest W, De Troy E, MacDonald K
Medical Devices: Evidence and Research 2015, 8:119-129
Published Date: 5 February 2015
Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor
Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2014, 4:1-9
Published Date: 12 March 2014
Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I
Clinical Ophthalmology 2013, 7:1849-1858
Published Date: 19 September 2013
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:55-62
Published Date: 27 August 2013
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia
Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2013, 3:45-53
Published Date: 27 August 2013
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:35-43
Published Date: 21 August 2013
Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia
Abraham I, MacDonald K
Biosimilars 2012, 2:13-25
Published Date: 6 September 2012